GlaxoSmithKline PLC on Tuesday said it had reached an eve-of-trial settlement resolving claims by several insurers that it misled them into paying $2.7 billion for drugs made at a Puerto Rico plant in an “egregious” violation of federal manufacturing standards.
The settlement resolves a long-running lawsuit that was set to go to trial on Tuesday in federal court in Philadelphia revolving around manufacturing issues at a now-closed GSK plant in Cidra, Puerto Rico.
To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/378QK4y
